{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-015373","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.922012+00:00","generated_at":"2026-06-15T21:37:06.069122+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xtant Medical Q1 revenue up 38% to $17.9M; initiates FY2023 guidance $73-75M","bullets":["Q1 2023 revenue of $17.9M, up 38% YoY (29% organic, 9% from Coflex acquisition).","GAAP net loss improved to $2.1M ($0.02/shr) vs $2.2M ($0.03) in prior year.","Non-GAAP adjusted EBITDA loss narrowed to $0.3M from $0.9M in Q1 2022.","Full-year 2023 revenue guidance of $73M-$75M, representing 26%-29% annual growth.","Gross margin expanded to 58.7% from 58.3%, driven by Coflex contribution."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-015373","json":"https://secwatch.observer/filing/0001493152-23-015373.json","markdown":"https://secwatch.observer/filing/0001493152-23-015373.md","text":"https://secwatch.observer/filing/0001493152-23-015373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:37:06.069122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66cd38096a3073785f08639229513e1361f2cf96","claim":"Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $73 million to $75 million. Guidance initiated.","evidence_excerpt":"Xtant Medical expects full year 2023 revenue of $73 million to $75 million, representing annual growth of approximately 26% to 29% compared to full year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$73 million to $75 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e721fce55c8e28e0e496294de6dbe87f56834d3e","claim":"Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $17.9 million, net income $2.1 million, or $0.02 per share, EPS $0.02 per share.","evidence_excerpt":"2023 Financial Results First quarter 2023 revenue grew 38%, including organic growth of 29% and a 9% contribution from the acquisition of the Coflex and CoFix product lines, to $17.9 million, compared to $13.0 million for the same period in 2022. The increase in revenue was attributed primarily to greater independent agent sales and sales from the recently acquired","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$17.9 million"},{"label":"Net income","value":"$2.1 million, or $0.02 per share"},{"label":"EPS","value":"$0.02 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}